Spots Global Cancer Trial Database for A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
Official Title: A Phase I Open-label, Multicenter Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
Study ID: NCT05735366
Conditions
Study Description
Brief Summary: This is a Phase 1 dose-escalation and expansion study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of SAIL66 in patients with CLDN6-positive locally advanced or metastatic solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
National Cancer Center Hospital, Tokyo, Chuo Ku, Japan
Cancer Institute Hospital of JFCR, Tokyo, Koto Ku, Japan
Shizuoka Cancer Center, Shizuoka, Sunto-gun, Japan
Contact Details
Name: Sponsor Chugai Pharmaceutical Co. Ltd
Affiliation: clinical-trials@chugai-pharm.co.jp
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
